Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06047080 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
A Phase 3 study of Large B-cell Lymphoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 1,130
- Enrollment target
- 20
- Study locations
NCT06047080 is a Phase 3 study of Large B-cell Lymphoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 1,130 participants, above the 119-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (850% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT06047080, a Phase 3 study of Large B-cell Lymphoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Glofitamab
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Polatuzumab vedotin
Study Locations (20)
California
- Kaiser Permanente - Anaheim (E. La Palma) - Anaheim
- University of California, San Francisco-Fresno - Clovis
- City of Hope National Medical Center - Duarte
- City of Hope - Lennar Foundation Cancer Center - Irvine
- Valkyrie Clinical Trials - Los Angeles
- UCLA Jonsson Comprehensive Cancer Center - Los Angeles
- Kaiser Permanente - Roseville - Roseville
- Kaiser Permanente - Santa Clara - Santa Clara
- Stanford Univ School of Med - Stanford
- Kaiser Permanente Medical Ctr - Vallejo
Colorado
- University of Colorado Cancer Center - Aurora
- Rocky Mountain Cancer Center - Denver - Littleton
Florida
- Miami Cancer Institute of Baptist Health, Inc. - Miami
- Memorial Cancer Institute at Memorial West - Pembroke Pines
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
- Illinois Cancer Care - Peoria
Alaska
- Alaska Oncology & Hematology, LLC - Anchorage
Connecticut
- Yale University School Of Medicine - New Haven
District of Columbia
- Medstar Franklin Square Medical Center - Washington D.C.
Hawaii
- Hawaii Cancer Care - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,130 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2030-10-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06047080
The ClinicalTrials.gov registry entry for NCT06047080 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,130 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 119-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (850% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06047080 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06047080 about?
NCT06047080 is a clinical study titled "An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma". The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
What is the current status of trial NCT06047080?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,130 participants. The study started on 2023-09-18. Estimated completion is 2030-10-30.
What conditions does trial NCT06047080 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma.
What interventions are being tested in trial NCT06047080?
The interventions under investigation include: Cyclophosphamide (DRUG), Glofitamab (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Polatuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT06047080?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06047080 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RECRUITING · Phase 3
-
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.